Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-DOPA-PET in Recurrent High-grade Glioma
NCT03242824Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Sep 2017
- Primary completion
- Jun 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Mayo Clinic. Primary endpoint: Progression-free Survival at 3 months. Started Sep 2017; status: completed.
Beyond the preview
Go deeper on NCT03242824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03242824.